Round-number milestones carry outsized weight in market psychology, and for a stock trading in the low $80s, $100 is the most natural aspirational target. Halozyme Therapeutics, Inc. (HALO) has already posted a roughly 39% gain over the past twelve months and hit a 52-week high of $82.99. The question now is whether enough fuel remains in the tank to push beyond that ceiling and into triple-digit territory for the first time in the company's history.
Halozyme is not a traditional drug developer. The San Diego-based biopharmaceutical technology company built its business around ENHANZE, a proprietary drug-delivery platform that uses the enzyme rHuPH20 to enable subcutaneous administration of biologic therapies that would otherwise require intravenous infusion. ENHANZE is embedded in over ten marketed products from partners including Johnson & Johnson, Roche, and argenx, generating royalty revenue that scales as those partnered drugs grow. The company also acquired hyperconcentration technologies through its Surf Bio and Elektrofi deals in late 2025, broadening its platform beyond ENHANZE. With 2026 total revenue guidance of $1.71 billion to $1.81 billion and non-GAAP EPS guidance of $7.75 to $8.25, Halozyme has laid out an ambitious growth roadmap.
The single biggest catalyst is the accelerating conversion of intravenous biologics to subcutaneous formulations. DARZALEX subcutaneous has already reached roughly 96% adoption in the U.S., and newer launches — including OCREVUS ZUNOVO, Opdivo Qvantig, Tecentriq Hybreza, and RYBREVANT SC — are still early in their adoption curves. Each new subcutaneous launch creates a fresh, multi-year royalty stream for Halozyme.
Management expects to sign one to three new ENHANZE deals in 2026 and has guided toward having fifteen partner programs in development by year-end. The company's recent global collaboration with Vertex Pharmaceuticals around Hypercon technology and the expanded partnership with Takeda for Entyvio demonstrate that the deal pipeline remains active. Additionally, a $1 billion share repurchase authorization should reduce the float and provide per-share earnings support, all else being equal.
Not everyone on Wall Street is convinced. Goldman Sachs carries a Sell rating with a $57 price target, arguing that current valuation already reflects optimistic assumptions. Patent challenges to the ENHANZE platform represent a persistent risk — if key intellectual property protections were weakened, the royalty model would come under direct pressure. There is also concentration risk: a significant portion of Halozyme's royalty revenue derives from a handful of blockbuster partnered drugs. Any slowdown in DARZALEX, Phesgo, or Vyvgart Hytrulo would have an outsized impact. Finally, Medicare Part B drug-pricing reform remains a wildcard that could compress the economics of physician-administered biologics, indirectly affecting royalty growth rates.
The analyst community is split. Among thirteen analysts covering HALO, eight rate the stock a Buy, four rate it Hold, and one — Goldman Sachs — rates it a Sell. The consensus twelve-month price target sits at approximately $81.60, implying essentially flat returns from the latest close. However, the bullish contingent sees substantially more upside: HC Wainwright maintains a $95 target, TD Cowen carries a Street-high $96, Morgan Stanley holds at $93, and Benchmark and UBS each target $90. For HALO to reach $100, it would need to exceed even the most optimistic Street estimate by roughly 4%, implying a degree of execution or multiple expansion beyond what any single analyst currently models.
HALO shares have traded in a well-defined uptrend since mid-2024, with the 200-day simple moving average providing consistent support during pullbacks. The stock cleared its prior all-time high near $82 in late July 2026, a breakout that bulls will want to see confirmed with follow-through buying. On the upside, $90 represents the first major psychological barrier and aligns with several analyst targets; a sustained move through that zone would put $100 within reach. On the downside, the $70–$72 area has served as significant support, reinforced by both the 50-day and 200-day moving averages. Any break below that range would likely postpone the $100 conversation indefinitely.
Navigating a stock with as many moving parts as Halozyme requires staying ahead of shifting market conditions. Tickeron's AI Daily Buy/Sell Signals continuously monitor thousands of stocks and ETFs, using artificial intelligence to generate Buy, Sell, or Hold signals based on evolving technical patterns, market data, and AI-driven analysis. Traders use these signals to identify emerging opportunities, manage existing positions, and spot trend changes before they become obvious to the broader market. For a stock like HALO that sits near all-time highs with a wide analyst disagreement, having an objective, data-driven signal can help separate genuine momentum from short-term noise.
HALO reaching $100 is ambitious but not implausible. The underlying business momentum is real: royalty revenues are growing at 30% to 35% year-over-year, new subcutaneous launches are expanding the addressable market, and the company's acquisitions of Elektrofi and Surf Bio extend its technology moat into the 2040s. Achieving $100 would require roughly 22% upside — equal parts earnings delivery and a modest re-rating from the current forward P/E multiple. The chief obstacle is that the market has so far been unwilling to award Halozyme a premium valuation, keeping the stock's multiple below many biotech peers despite superior growth. For $100 to become reality, Halozyme likely needs at least two of the following: one or more high-profile new ENHANZE deals, a meaningful beat-and-raise quarter, and a resolution to patent uncertainty that removes a persistent overhang. Investors should watch the Q2 2026 earnings report on August 6 for the next major checkpoint.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, HALO has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if HALO jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To HALO | 1D Price Change % | ||
|---|---|---|---|---|
| HALO | 100% | -2.00% | ||
| AXON - HALO | 47% Loosely correlated | -0.45% | ||
| INCY - HALO | 38% Loosely correlated | -0.30% | ||
| GMAB - HALO | 37% Loosely correlated | +1.91% | ||
| VCYT - HALO | 34% Loosely correlated | -3.17% | ||
| ONC - HALO | 33% Loosely correlated | -2.40% | ||
More | ||||